MRT-2359

Product

Last mentioned: Mar 19, 2026

Timeline

Mar 17, 2026
Q4 2025 Earnings

Reported year-end financial results and updated 2027 cash runway.
2026
Anticipated Milestone

Expected Phase 1 data readout for MRT-6160 in autoimmune diseases.
Jun 15, 2025
MRT-2359 Update

Released preliminary Phase 1 safety and target engagement data.
Oct 28, 2024
Novartis Partnership

Signed global licensing deal for MRT-6160 worth up to $2.1B.

Stories mentioning MRT-2359 1

pharma Neutral

Monte Rosa Therapeutics Leverages Novartis Deal to Extend Runway into 2027

Monte Rosa Therapeutics reported quarterly results highlighting a robust cash position following its $2.1 billion Novartis partnership. The company is accelerating its molecular glue degrader pipeline with a strategic pivot toward high-value immunology indications.

Mar 19, 2026 2 sources